Presentation is loading. Please wait.

Presentation is loading. Please wait.

2012/09/27 Combine meeting 58 y/o Female DCMP s/p ECMO s/p DFPP s/p LVAD 林柑 5305996.

Similar presentations


Presentation on theme: "2012/09/27 Combine meeting 58 y/o Female DCMP s/p ECMO s/p DFPP s/p LVAD 林柑 5305996."— Presentation transcript:

1 2012/09/27 Combine meeting 58 y/o Female DCMP s/p ECMO s/p DFPP s/p LVAD 林柑

2 Brief History DCMP ICD Heart transplantation waiting list

3 58 yo Female DCMP with arrhythmia status post permanent pacemaker insertion. 2012/07/07 HsinChu H.: unsteady gait and aphasia. Con’s=E4M6Vt Brain CT: left cerebral subcortical infarction  admission 2012/07/07-11: Progressive dyspnea, oliguria LVEF=4.6%  Pulmonary edema with acute CHF 2012/07/11: Intubation, ECMO  NTUH

4 Physical Examination (2012/7/11) Vital Sign: T:36.2 P:64 R:17 BP:108/84 mmHg General appearance: ill Consciousness: E4M6Vt HEENT: grossly normal Eyes: conjunctiva: not pale, sclera: not icteric Pupil Isocoric, light reflex (R/L): +/+, prompt Ears: eardrums not injected. Neck: supple, JVE (-), LAP (-) Chest: symmetric expansion, bil crackles (+), Heart: RHB, no murmur audible Abdomen: soft and flat, no superficial collateral circulations, No tenderness, no rebounding tenderness Bowel sounds: normal active Liver / Spleen: Not palpable Extremities: freely movable, pitting edema (+), cyanosis (-), petechiae (-), rash (-) left femoral ECMO (+)

5 X-ray

6 2012/07/12 EKG

7 2012/07/16 Cardiac Echo LVEF=14.6% global hypokinesia Moderate MR, TR, PR, Pulmonary Hypertension TRPG=50.7

8 CAVH on V-A ECMO AKI due to shock related CAVH on ECMO support Waiting for heart transplantation

9 Lab data 5.4 Donor Crossmatch + Unasyn Tatumcef

10 Cross match Date 4 ℃ T-cell37 ℃ B-cell4 ℃ T-cell37 ℃ B-cell HLA-ABCHLA-DR :2 Positive 1:16 Positive 1:1 Positive 1:16 Positive A2 A24 B38 B46 Bw4 Bw6 Cw1 Cw7 DR17 DR19 DR52 DR53 DQ2 DQ :33 1:8 Positive 1:32 Positive 1:2 Positive 1:32 Positive :41 Negative1:16 Positive Negative1:32 Positive  減敏感治療

11 Desenstitration Order

12 DFPP Protocol 1.2A  4A Separator 2.Volume : 1.5 X 3.30%  10% Extraction 4.Replacement Fluid : Nil

13 DFPP Course Volume /blood flow Duration Extraction (L) Complication A 3500/ min0.26BP drop, wound oozing A 3500/ min0.37BP drop, wound oozing A 3500/ min0.42BP drop, wound oozing A 2300/10077 min0.31 ?ABP straight line A 3500/ min0.42Wound oozing A 3500/ min0.36Wound oozing A 3500/ min0.48Wound oozing A 3500/ min0.44Wound oozing

14

15 Treatment Course AlbuminFibrinogenTransfusionaPTT/INRHeparin ﹡ / /1.09 ﹡ / /1.220 ﹡ /1.130 ﹡ /1.040 ﹡ /0.990 ﹡ /1.230 ﹡ /1.100 ﹡ / / /1.400

16

17

18 Donor Cross match Date 4 ℃ T-cell4 ℃ B-cell37 ℃ T-cell37 ℃ B-cell Anti-HLA class I Ab Anti-HLA class I I Ab Flow PRA Class I Flow PRA Class II :2 Positive 1:16 Positive 1:1 Positive 1:16 Positive Negative Positive :33 1:8 Positive 1:32 Positive 1:2 Positive 1:32 Positive :41 Negative1:16 Positive Negative1:32 Positive :44 1:32 Positive :1 Positive 1:8 Positive 1:1 Positive 1:4 Positive

19 問題 Blood flow ? Myocardium depression Fibrinogen consumption – Bleeding – Transfusion 輸血 – 避免輸血 – 前置作業

20 Treatment Course in 5CVI 2012/07/14 ECMO+CAVH, on HTx waiting list, PRA(+) 2012/07/25 Start Desensitization Protocol 7/25 Rituximab 200 mg iv stat with solu-medrol 40 mg st 7/26 DFPP(2A) with IVIG 7/26, 7/28, 7/30 8/1~14 DFPP (4A) with IVIG (QW2,5)  8 courses

21 Treatment Course in 5CVI 2012/07/11-8/30: Waiting for Heart Transplantation (ECMO) ‧ Coagulopathy DFPP + IVIG for desensitization  low fibrinogen, bleeding Thrombus formation s/p emergent evacuation *4 PRA(+) VT  DC shock (7/29, 8/27,8/28)

22 2012/08/30 LVAD implantation OP Method: LVAD THORATEC implantation V cannula: beveled tip against septim through LV apex A cannula: 14mm graft end-to-side anastomosis to AsAo; then wrapped by 20mm Hemashield vascular graft.

23 Post-OP Course (2012/8/30) 2012/08/30 14:00 Thoratec blood flow: 6L/min CVP:24 mmHg, BP:45/42(43) mmHg Dopamine :9.4 µg/Kg/min Levophed: 1.63 µg/Kg/min, Isuprel : 0.2 µg/Kg/min 2012/08/30 18:00 BP↓ (48/41mmHg), device alarm: no flow EKG: bradycardia Lab: Hyperkalemia(K6.18) with metabolic cidosis (pH=7.05) s/p correction: BP 169/97, PH 7.546, K 2.90 Start CVVH

24 Post-OP Course (2012/8/30) 2012/08/ :00 BP drop ↓77/52mmHg VAD alarm(+): poor drainage CVP 27  12  volume challenge! Dop+Isuprel+Levophed+ DC shock*2  CPR-> on ECMO

25 2012/8/30-31 ABG: lactate↑

26 Treatment Course in 5CVI 2012/08/31 Pupil dilatation, E1M1Vt BP:50/30mmHg Discuss with family about poor prognosis 2012/09/02 Remove ECMO and Thoratec, the pt expired at 11:10AM

27

28 問題 Blood flow ? Myocardium depression Fibrinogen consumption – Bleeding – Transfusion 輸血 – 避免輸血 – 前置作業

29 The decrease of patient blood volume was induced by an oncotic pressure drop due to albumin loss and often resulted in a pressure drop.

30 ECMO + DFPP

31 Intraoperative plasmapheresis and Cellcept induction Peri-operative alemtuzumab(Campath-1H) and plasmapheresis for high-PRA positive lymphocyte crossmatch heart transplant: a strategy to shorten left ventricular device support. – Department of surgery, University of Texas Medical Branch, Galveston. – J Heart Lung Transplant Sep;27(9): Mortality and morbidity in pre-sensitized pediatric heart transplant recipients with a positive donor crossmatch utilizing peri-operative plasmapheresis and cytolytic therapy. – Department of Pediatrics, Washington University school of Medicine. – J Heart Lung Transplant Sep;26(9): Pediatric cardiac transplantation in children with high panel reactive antibody. – The Congenital Heart institute of Florida, All children’s Hospital, University of South Florida. – Ann Thorac Surg Nov;78(5):1703-9

32

33 Protocol 3-volume exchange in min, depending on the patient’s body size. Repaid removal of calcium and heparin sulfate during pheresis. The timing of the institution of CPB and pheresis is determined by the expected arrival of the donor heart.

34 Ann Thorac Surg 2011;92:

35 NTUH Plasma exchange during CPB

36

37 EvafluxPore sizeAlbumin sc IgG sc HDL sc IgM sc LDL 2A 0.01 ㎛ A 0.02 ㎛ A 0.03 ㎛ A 0.03 ㎛ (?) 移除目標為 IgG: 2A 或 3A (can remove Immunoglobulins while allowing Albumin to be returned) 移除目標為 IgM: 4A 或 5A 移除目標為 LDL: 5A (can remove LDL while allowing Albumin and HDL to be returned)

38 楊正智 order

39 楊正智 DFPP

40 4/18 plasma exchange in OR

41

42

43 LVAD (Thoratec Heartmate VE) Pulsatile, LV assist Only. Fixed rate / Chamber filled (asynchrony) – Initiated with flow 2.2L/min/m 2, LAP 10-15mmHg Bridge to Heart Transplantation.

44 Manual Of Perioperative Care In Adult Cardiac Surgery Ch11 p.479

45 Contraindication Reasonable chance of recovery? – Age, medical condition, RV function, – Comorbidities ( neurologic, pulmonary, renal, hepatic) – Other medical issues ( infection, vascular disease, DM…)

46 Post-LVAD management Adequate tissue perfusion – Assessed by mixed Venous oxygen saturation Decrease myocardial demand – Vasoactive medication only for RV function or increased SVR to keep MAP>75mmHg – “vasodilatory shock”

47 Complication Mediastinal bleeding, tamponade (60%) – Manifested by inadequate drainage into the device. – Previous coagulopathy, fibrinolysis, plt dysfxn. Mediastinitis and Sepsis (40-50%) – Device related. – Resistant organism. Malignant ventricular arrhythmia – LVAD flow↓ – Foster thrombus formation RV failure (20%)  iNO Thromboembolism (20%)

48 Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) trial; N=280. The 1-year survival after LVAD implantation was 56%; in-hospital mortality after LVAD surgery was 27%. – The most important determinants: poor nutrition hematological abnormalities end-organ or right ventricular dysfunction lack of inotropic support Circulation Jul 31;116(5): Epub 2007 Jul 16

49 Preoperative RV dysfunction correlated well with postoperative worsening RV dysfunction. – deviation of interventricular septum towards the LV, which eliminates the septal contribution to right heart contractility. Neragi-Miandoab et al. Journal of Cardiothoracic Surgery 2012, 7:60a

50 Operative mortality of 46% for a score > 5. 12% for a score to <=5. J Thorac Cardiovasc Surg 2003;125:855-62

51 Back to our patient and Questions Pre-LVAD status: – prolonged ECMO support  end organ damage? – profound coagulopathy – PRA(+)  Increase peri-operative mortality


Download ppt "2012/09/27 Combine meeting 58 y/o Female DCMP s/p ECMO s/p DFPP s/p LVAD 林柑 5305996."

Similar presentations


Ads by Google